Insmed, Inc. (NASDAQ:INSM) Director Melvin Md Sharoky sold 50,000 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total transaction of $1,368,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Insmed, Inc. (NASDAQ:INSM) opened at 30.04 on Friday. The company’s market capitalization is $1.87 billion. Insmed, Inc. has a 52-week low of $10.21 and a 52-week high of $31.39. The company’s 50-day moving average is $15.49 and its 200-day moving average is $16.45.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.09. On average, analysts expect that Insmed, Inc. will post ($2.70) earnings per share for the current fiscal year.

WARNING: “Insmed, Inc. (INSM) Director Sells $1,368,500.00 in Stock” was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/10/insmed-inc-insm-director-sells-1368500-00-in-stock.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Russell Investments Group Ltd. lifted its holdings in Insmed by 219.7% during the first quarter. Russell Investments Group Ltd. now owns 57,926 shares of the biopharmaceutical company’s stock valued at $1,014,000 after purchasing an additional 39,805 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Insmed by 4.1% during the first quarter. Bank of New York Mellon Corp now owns 314,494 shares of the biopharmaceutical company’s stock valued at $5,507,000 after purchasing an additional 12,336 shares during the last quarter. Pictet Asset Management Ltd. lifted its holdings in Insmed by 97.2% during the first quarter. Pictet Asset Management Ltd. now owns 124,543 shares of the biopharmaceutical company’s stock valued at $2,181,000 after purchasing an additional 61,400 shares during the last quarter. Swiss National Bank lifted its holdings in Insmed by 4.9% during the first quarter. Swiss National Bank now owns 96,800 shares of the biopharmaceutical company’s stock valued at $1,695,000 after purchasing an additional 4,500 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Insmed by 39.2% during the first quarter. Parametric Portfolio Associates LLC now owns 14,417 shares of the biopharmaceutical company’s stock valued at $252,000 after purchasing an additional 4,063 shares during the last quarter. 89.64% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently weighed in on the stock. Evercore ISI increased their price objective on shares of Insmed from $28.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, September 5th. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Wednesday, July 5th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Insmed in a research report on Wednesday. Robert W. Baird reaffirmed a “positive” rating and set a $32.00 price target (up from $23.00) on shares of Insmed in a research report on Wednesday. Finally, Citigroup Inc. reaffirmed a “neutral” rating and set a $17.00 price target (up from $14.00) on shares of Insmed in a research report on Sunday, June 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $34.50.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.